UK’s NICE recommend pemigatinib (Pemazyre®) for FGFR2+ cholangiocarcinoma

The UK’s National Institute for Health and Care Excellence (NICE) recently published final draft guidance recommending pemigatinib (Pemazyre®) for the treatment of locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. The treatment is an option for adults whose cancer has progressed after chemotherapy. NICE’s guidance will enable all eligible patients in England and Wales to have access to pemigatinib through the National Health Service (NHS). Pemigatinib is the first ever treatment indicated specifically for cholangiocarcinoma in the UK and Europe, and the first targeted therapy for FGFR2 fusion positive disease. Eligible patients...